0.2531  0.011 (4.59%)		12-23 16:00
Open: 0.251 High: 0.29 Volume: 906,395		Pre. Close: 0.242 Low: 0.2421 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Bionomics Limited is an Australian biopharmaceutical company operating at the clinical stage, dedicated to the discovery and advancement of innovative therapeutic compounds. Its research efforts primarily target central nervous system disorders and various cancers, with operations spanning Australia and the United States. A key experimental medicine in its portfolio is BNC210. This compound, which functions as a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, has successfully concluded Phase 2 trials for addressing social anxiety disorder and post-traumatic stress disorder. The company is also developing BNC375, a small molecule therapeutic aimed at improving cognitive function in patients suffering from Alzheimer's disease. Another asset, BNC101, a monoclonal antibody engineered to target cancer stem cells, has concluded its Phase 1 clinical assessment. Moreover, Bionomics is advancing BNC105, a vascular disrupting agent. This agent is currently in Phase 2 clinical trials for the treatment of refractory colorectal cancer and in Phase 1 trials for individuals with relapsed/refractory chronic lymphocytic leukemia. Further bolstering its capabilities, Bionomics Limited maintains a licensing agreement with the pharmaceutical giant Merck & Co., Inc. Established in 1996, the company maintains its corporate headquarters in Eastwood, Australia.

Fri, 08 Nov 2024
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewswire

Tue, 01 Oct 2024
Bionomics Limited announces intention to re-domicile to the United States - Yahoo Finance

Sat, 27 Jul 2024
Bionomics Limited (NASDAQ: BNOX) - Share Price - intelligentinvestor.com.au

Fri, 19 Jul 2024
Get insights into the top gainers and losers of Friday's pre-market session. - ChartMill

Fri, 01 Dec 2023
Bionomics Reports Positive Phase 2b Results for BNC210 in Post-Traumatic Stress Disorder Trial - BioPharma APAC

Thu, 28 Sep 2023
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date